Related Experiment Videos
[Dyslipoproteinemia in elderly patients]
V Bláha1, D Solichová, Z Zadák
1Klinika gerontologická a metabolická Fakultní nemocnice UK, Hradec Králové.
Insights
Dyslipoproteinaemia remains a key risk factor for cardiovascular disease in the elderly, with lipid levels still predictive. Treatment strategies emphasize individualized approaches, diet, exercise, and pharmacotherapy for high-risk individuals.
Area of Science:
- Cardiology
- Geriatrics
- Metabolic Disorders
Context:
- Dyslipoproteinaemia is a significant risk factor for atherosclerotic cardiovascular diseases (ASCVD).
- The predictive value of lipid profiles (total cholesterol, LDL-C, HDL-C, triglycerides, lipoprotein(a)) is maintained in the elderly population.
- Post-hoc analyses of major clinical studies provide data on managing dyslipoproteinaemia in older adults.
Purpose:
- To review the role of dyslipoproteinaemia in ASCVD among the elderly.
- To discuss current treatment guidelines and strategies for dyslipoproteinaemia in older individuals.
- To highlight the importance of individualized treatment approaches.
Summary:
- Lipid levels remain predictive of cardiovascular risk in the aged.
- Treatment decisions for dyslipoproteinaemia in the elderly are guided by individual risk factors and clinical guidelines, often continuing treatment for genetic forms.
- Patients with coronary heart disease (CHD) or subclinical CHD benefit significantly from lipid-lowering interventions, with up to a 45% reduction in CHD risk.
- Diet and exercise are foundational, while pharmacotherapy (statins, fibrates) is reserved for high-risk patients, initiated at lower doses with careful monitoring for adverse effects.
Impact:
- Informs clinical practice regarding the management of dyslipoproteinaemia in elderly patients.
- Emphasizes a personalized approach to cardiovascular risk reduction in older adults.
- Highlights the continued relevance of lipid management in preventing ASCVD events in the aging population.
Abstract:
Dyslipoproteinaemia as one among classical risk factors of atherosclerotic cardiovascular diseases has been involved also in the aged. The predictive value of total cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerols and lipoprotein (a) is preserved. There are several objective data from post-hoc analyses of prospective clinical studies AFCAPS/TexCAPS, 4S, CARE, LIPID a WOSCOPS, which addressed the need of treatment of dyslipoproteinaemia in the aged. The guidelines are not unique, but they stress an individual approach. We usually continue to treat genetic forms of dyslipidaemia. Candidates of treatment are also patients with diagnose of coronary heart disease (CHD) and sublinic form of CHD, where the treatment has been effective within two years and lead to decrease of CHD risk up to 45%. The individuals with CHD and other CHD risk factors absent would be treated less often. The diet is an basic treatment option of hypolipidemic intervention in the elderly. We do not omit exercise. The pharmacotherapy of dyslipidaemia is used for the individuals with high risk. We usually start with lower dose of fibrates or statins and monitor for adverse effects of such therapy.